Does the subtype of acute coronary syndrome treated by percutaneous coronary intervention predict long-term clinical outcomes?
Access Status
Authors
Date
2018Type
Metadata
Show full item recordCitation
Source Title
ISSN
School
Funding and Sponsorship
Collection
Abstract
© The Author 2017. Aims The prognosis of patients undergoing percutaneous coronary intervention (PCI) for different subtypes of acute coronary syndromes (ACS) remains unclear. We compared short- and long-term mortality in patients undergoing PCI for unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). Methods and results This was a retrospective cohort study of 13 184 patients (5966 STEMI, 5307 NSTEMI, and 1911 UA) undergoing PCI between 1 January 2005 and 30 November 2013 in a multi-centre registry. Clinical and procedural characteristics, as well as outcomes, were compared by ACS subtype. Long-term all-cause mortality data were obtained via linkage to the National Death Index (NDI). Patients with STEMI compared with NSTEMI and UA were younger (62.9 ± 12.8 vs. 64.7 ± 12.5 vs. 65.5 ± 11.8 years; P < 0.01), had fewer comorbidities including diabetes, heart failure, and previous myocardial infarction (all P < 0.01). Procedural success was similar across all groups (P = 0.54). In-hospital, 30-day and 1-year all-cause mortality increased significantly from UA to NSTEMI to STEMI patients (1-year mortality 2.5% vs. 4.5% vs. 8.7%; P < 0.01). Kaplan-Meier survival estimates showed increased early mortality in the STEMI group (log-rank P < 0.01). However, after approximately 8.2 years, survival was similar across all groups. In a proportional-odds model using flexible parametric survival modelling, ACS subtype was not an independent predictor of NDI-linked mortality [UA: odds ratio (OR) 0.85, 95% CI 0.71-1.02; STEMI: OR 1.01, 95% confidence interval (CI) 0.88-1.16; NSTEMI as reference category]. Conclusion Despite disparate baseline characteristics and differences in short-term mortality, long-term mortality was similar across the spectrum of ACS treated by PCI and contemporary medical therapy.
Related items
Showing items related by title, author, creator and subject.
-
Fernando, H.; Duffy, S.J.; Low, A.; Dinh, D.; Adrianopoulos, N.; Sharma, A.; Peter, K.; Stub, D.; Leong, K.E.; Ajani, A.; Clark, D.; Freeman, M.; Sebastian, M.; Brennan, A.; Selkrig, L.; Reid, Christopher ; Kaye, D.; Oqueli, E. (2021)The short- and long-term implications of identifying totally occluded culprit coronary arteries (TOCCA) in patients presenting with non-ST-elevation myocardial infarction (NSTEMI) have not been well studied. This study ...
-
Yudi, M.; Ramchand, J.; Farouque, O.; Andrianopoulos, N.; Chan, W.; Duffy, S.; Lefkovits, J.; Brennan, A.; Spencer, R.; Fernando, D.; Hiew, C.; Freeman, M.; Reid, Christopher; Ajani, A.; Clark, D. (2016)© 2016Background Door-to-balloon time (DTBT) less than 90 min remains the benchmark of timely reperfusion in ST-elevation myocardial infarction (STEMI). The relative long-term benefit of timely reperfusion in STEMI patients ...
-
Prosser, H.C.; Peck, K.Y.; Dinh, D.; Roberts, L.; Chandrasekhar, J.; Brennan, A.; Duffy, S.J.; Clark, D.; Ajani, A.E.; Oqueli, E.; Sebastian, M.; Reid, Christopher ; Freeman, M.; Sajeev, J.K.; Teh, A.W. (2022)Aims: The use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II-receptor blockers (ARBs) post-myocardial infarction (MI) is supported by evidence based on trials performed in the thrombolysis era. This ...
